Silence Therapeutics (SLN) Prepaid Assets (2023 - 2026)
Silence Therapeutics (SLN) posted Prepaid Assets of $10.6 million for Q1 2026, down 8.49% sequentially from $11.5 million in Q4 2025, and down 35.7% YoY from $16.4 million in Q1 2025.
Analysis
Silence Therapeutics (SLN) Prepaid Assets (2023 - 2026) Analysis & Trends
Silence Therapeutics has reported Prepaid Assets for 9 years, with the latest figure at $10.6 million in Q1 2026.
- Quarterly Prepaid Assets fell 35.7% year-over-year to $10.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.6 million (down 35.7% YoY) and the FY2025 annual result came in at $11.5 million, down 21.32% from the prior year.
- Prepaid Assets slipped to $10.6 million in Q1 2026 per SLN's latest filing, from $11.5 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $16.4 million in Q1 2025 and troughed at $9.3 million in Q3 2025.
- A 5-year average of $12.2 million and a median of $11.4 million in 2025 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2022 and 2026: Prepaid Assets surged 65.58% in 2022, then tumbled 35.7% in 2026.
- Over 5 years, Prepaid Assets stood at $9.6 million in 2022, then grew by 17.88% to $11.3 million in 2023, then gained by 29.34% to $14.7 million in 2024, then retreated by 21.32% to $11.5 million in 2025, then slipped by 8.49% to $10.6 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $10.6 million, $11.5 million, and $9.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Silence Therapeutics | 690.60 Mn | 618.50 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.94 Mn |
| Mar 31, 2026 | 10.56 Mn |
| Dec 31, 2025 | 11.54 Mn |
| Sep 30, 2025 | 9.26 Mn |
| Jun 30, 2025 | 14.36 Mn |
| Mar 31, 2025 | 16.42 Mn |
| Dec 31, 2024 | 14.66 Mn |
| Dec 31, 2023 | 11.63 Mn |